Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Pechala's Reports
$25.00
Provider: New Constructs, LLC
$25.00
Provider: Jefferson Research
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Celldex Therapeutics Inc's CDX-011 Demonstrates High Response Rates In Patients With Metastatic Breast Cancer Expressing Elevated Levels Of GPNMB And In Triple Negative Disease


Wednesday, 23 May 2012 04:01pm EDT 

Celldex Therapeutics, Inc announced preliminary results from the Company’s randomized Phase 2b EMERGE study of CDX-011 (glembatumumab vedotin) antibody drug conjugate in patients with glycoprotein NMB (GPNMB) expressing, advanced, heavily pretreated breast cancer. Preliminary results suggest that CDX-011 induces impressive response rates compared to current, available therapies in patients with advanced, refractory breast cancers with high GPNMB expression (expression in ≥25% of tumor cells). In this high expressing patient population, treatment with CDX-011 resulted in a 32% overall response rate, whereas treatment with Investigator’s Choice single-agent chemotherapy resulted in a 13% ORR. CDX-011 also demonstrated response rates in patients with triple negative breast cancer across all levels of GPNMB expression (CDX-011 ORR of 21%; IC ORR of 0%), where treatment options are extremely limited. In addition, in patients with triple negative breast cancer who also express GPNMB, greater activity was observed (CDX-011 ORR of 36%; IC ORR of 0%). The ORR across all levels of GPNMB expression was 19% for the CDX-011 arm and 14% for the IC arm, and a direct, positive correlation was observed between increasing levels of GPNMB expression and increased CDX-011 response rates. Based on these data, the Company believes CDX-011 has promise as a targeted therapy for patients with breast cancer and high expression of GPNMB, and especially for those with triple negative disease. 

Company Quote

14.24
-0.45 -3.06%
17 Apr 2014